Welcome to Taixing Joxin Bio-tec Co., Ltd. Website!

中文版 | ENGLISH

NEWS

China invests 30 billion in developing medical technology

   

The National Health Program Committee held a regular press conference on September 10. Qin Huaijin, director of the Ministry of Science and Education of the State Health and Family Planning Commission pointed out that since the 12th Five-Year Plan, China has closely organized a number of key projects such as science and technology major projects in the fields of medicine and health, focusing on national strategies and people's health needs. 30 billion yuan, the output of a large number of international level of results.

Journal of Medical Science and Technology

Qin Huaijin said that from 2010 to 2014, China's total SCI SCI papers more than 230,000, ranking second in the world; since 2011, pharmaceutical patent applications have been ranked first in the world; genomics, stem cells, immunology And other basic research areas have reached the international advanced level for disease diagnosis and control technology and product development has laid a solid foundation. The development of medical and health technology, and promote the development of the pharmaceutical industry, to solve major health problems, improve the health level provides a strong support.

Significant progress in the prevention and treatment of major noncommunicable diseases

In the prevention and control of major non-communicable diseases, China's key disease prevention and control technology has made great progress, disease prevention, diagnosis, treatment, rehabilitation techniques and strategies constantly updated, in order to reduce the incidence of early diagnosis and treatment, to improve the treatment effect, Pain and economic burden to provide a steady stream of new technologies, new drugs, new methods, new strategies.

Cardiovascular and cerebrovascular disease prevention and control more adapt to national conditions

In the prevention and treatment of cardiovascular and cerebrovascular diseases, cardiovascular and cerebrovascular disease cohort study made a breakthrough, to explore a set of characteristics for the crowd of hypertension control, stroke prevention and management and management model. In the field of craniocerebral surgery to obtain a number of key technological breakthroughs, and further optimize the surgical treatment programs, such as brain stem tumors and other difficult encephalopathy surgical methods, significantly improve the survival rate and quality of life of patients with neurosurgery into the world's leading ranks.

Strengthen the early diagnosis and treatment of cancer prevention and treatment, improve the rate of early diagnosis

In the prevention and treatment of cancer, for our common lung cancer, liver cancer, esophageal cancer, leukemia, focusing on strengthening the early diagnosis and technology research and development, improve the rate of early diagnosis; developed a number of clinical diagnosis and treatment and key technologies to standardize and precision treatment The degree of greatly improved. Wang Zhenyi academicians after years of research, proposed acute promyelocytic leukemia induced differentiation therapy, and created a combination of trans-retinoic acid and arsenic oxide treatment of acute promyelocytic leukemia precedent, the five-year survival rate increased to 95% Acute promyelocytic leukemia is the first curable adult leukemia.

New diagnostic techniques and other infectious diseases prevention and control technology to further enhance

Qin Huaijin said that for infectious diseases, China's prevention and control capacity has been further improved. "Eleventh Five-Year" since the country to AIDS, viral hepatitis and tuberculosis and other major infectious diseases as the focus, continue to increase scientific and technological research efforts in the new diagnostic techniques, optimize clinical treatment programs, comprehensive prevention and control strategies and measures to obtain a series Breakthrough, in order to reduce the new infection rate and mortality to provide a technical support. China's independent research and development of HIV nucleic acid detection reagents, so that the detection window period from 22 days to 11 days, has been put into use in the national blood bank, effectively improve the blood safety and security capabilities for the early detection of AIDS and control the spread of the play Important role; in order to solve the problem of high mortality of severe liver disease, China's independent research and development of artificial liver system, the acute and subacute severe hepatitis mortality rate from 88% to 21%, chronic severe hepatitis mortality rate from 85% to 57% ; New Mycobacterium tuberculosis rapid detection reagents to improve the detection rate by 20%.

This paper has strengthened the technical system and capacity building, and built a network system covering the whole country to deal with the prevention and control technology of new infectious diseases. In order to solve the problems of the new infectious diseases, , Breakthrough pathogen combination screening and other key technologies, so that the new outbreak of infectious disease pathogens identification ability to achieve the international advanced level, the establishment of emergency drugs and vaccine research and development, emergency treatment and other technical platforms, significantly enhance the emergency response The ability to deal with the transition from passive to active response.

HOME | ABOUT US | PRODUCTS | NEWS | FACTORY | HONORS | CONTACT | 中文版

Taixing Joxin Bio-tec Co., Ltd.

Add : No.88, chengdong industrial park, taixing, jiangsu China.  Zip : 225400

General Manager: Yao Hengjun  Mobile : +86-13615177555

Tel : +86-523-87558858  Fax : +86-523-87558858  E-mail : yhj@joxbio.com  QQ:184089063

Marketing Department Tel : +86-523-87612088,87558858 

Mobile : +86-15371578585    Fax : +86-523-87558858

Copyright(C)2017, Taixing Joxin Bio-tec Co., Ltd. All Rights Reserved. Supported by ChinaChemNet ChemNet Toocle Copyright Notice 備案字號:蘇ICP備17043593號

蘇公網安備 32128302001353號

 
點擊這里給我發消息
李小姐
點擊這里給我發消息
總經理 姚恒俊
 
 
 
 
亚洲精品亚洲人成在线下载